Literature DB >> 8030396

Neuro-ophthalmic manifestations of the syndrome of ophthalmoplegia, ataxia and areflexia: a review.

S N al-Din1, M Anderson, O Eeg-Olofsson, J V Trontelj.   

Abstract

Controversy regarding the nosological position of the syndrome of ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome) exists. The oculomotor dysfunction was presumed to represent an unusually symmetrical peripheral cranial nerve dysfunction. To investigate the neuro-ophthalmic manifestations in this rare syndrome we reviewed 109 reports describing 243 cases. The ophthalmoplegia was remarkable in its constant association with a cerebellar type ataxia. It was described to be remarkably symmetrical at all stages of development and recovery. From the early description of the syndrome by Fisher the ophthalmoplegia was observed to evolve as a symmetrical failure of upgaze followed by loss of lateral gaze and last by downgaze, recovery develops in the opposite pattern. Despite the severe nature of the ophthalmoplegia, 58 patients were reported to have sparing of downgaze and 192 (79%) had relative sparing of the eye lids. Active lid retraction and preserved Bell's phenomenon, despite upgaze paralysis, were described in 22 and 15 patients respectively. Upper lid jerks were described in 2, Parinaud's syndrome in 2, convergence spasm in 6, internuclear ophthalmoplegia in 15 and horizontal dissociated nystagmus in 11. Interestingly 23 were reported to present with paralysis of abduction progressing to lateral gaze paralysis and 5 had paralysis of abduction and contralateral gaze paralysis. Four had defective vestibulo-ocular reflex despite recovery of upgaze, 10 had central type nystagmus including rotatory, retractory and rebound nystagmus. Relative preservation of optokinetic nystagmus and preservation of vestibulo-ocular reflex despite an otherwise complete ophthalmoplegia were reported in 6 and 2 patients respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8030396     DOI: 10.1111/j.1600-0404.1994.tb01654.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  9 in total

Review 1.  [Miller Fisher syndrome: case report and review with discussion of differential diagnosis and nosology].

Authors:  U Becker; G Gahn; H Reichmann; B Herting
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

2.  Miller Fisher syndrome in infancy.

Authors:  J Benito-León; J Bravo; F Mateos; R Simón
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

3.  Late Presentation of Ataxia, Areflexia, and Electrophysiological Abnormalities as Part of Miller Fisher Syndrome: Case Report.

Authors:  Deniz Somer; Arzu Yilmaz; Serap Tiras Teber; Fatma Gul Cinar
Journal:  Neuroophthalmology       Date:  2016-06-08

4.  Anti-GQ1b IgG antibody syndrome: clinical and immunological range.

Authors:  M Odaka; N Yuki; K Hirata
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-01       Impact factor: 10.154

5.  Pupillary Involvement in Miller Fisher Syndrome.

Authors:  Bahar Kaymakamzade; Ferda Selcuk; Aydan Koysuren; Ayse Ilksen Colpak; Senem Ertugrul Mut; Tulay Kansu
Journal:  Neuroophthalmology       Date:  2013-05-31

6.  Miller Fisher-Guillain-Barré overlap syndrome with enhancing lesions in the spinocerebellar tracts.

Authors:  M Urushitani; F Udaka; M Kameyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

7.  Cd2+, Mn2+, Ni2+ and Se2+ toxicity to Saccharomyces cerevisiae lacking YPK9p the orthologue of human ATP13A2.

Authors:  Karyn Schmidt; Devin M Wolfe; Barbara Stiller; David A Pearce
Journal:  Biochem Biophys Res Commun       Date:  2009-04-05       Impact factor: 3.575

8.  Mydriasis with light-near dissociation in Fisher's Syndrome.

Authors:  Takuya Nitta; Manabu Kase; Yasuhiro Shinmei; Kazuhiko Yoshida; Shinki Chin; Shigeaki Ohno
Journal:  Jpn J Ophthalmol       Date:  2007-06-07       Impact factor: 2.447

9.  Parkinson's disease: from genetics to clinical practice.

Authors:  Jordi Clarimón; Jaime Kulisevsky
Journal:  Curr Genomics       Date:  2013-12       Impact factor: 2.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.